One method of overcoming the discrepancy between treatment prescribed and that actually taken is to give a single dose, the taking of which can be observed by the prescribing doctor. This paper reports the results of a trial to investigate the possibility of using single doses of metronidazole in the treatment of Trichomonas vaginalis infections in women.
what tedious. Subsequently May and Baker were able to supply 400 mg. tablets that are only slightly larger than the original 200 mg. size. The tablets were taken under supervision and the patients were asked to return in one week and again after one month for repeat tests; further visits were made at the discretion of the patient, but an interval of at least 3 months elapsed in the case of each patient before the results were reviewed.
The criteria for diagnosis and tests of cure, although quite satisfactory for routine clinic work, might be judged insufficient for a scientific study, and so it was decided to establish a control group by the same criteria but employing the standard course of metronidazole 200 mg. three times daily for 7 days. Use of a control group lessened the difficulty of establishing whether a recurrence of trichomoniasis was due to treatment failure or to re-infection, because the results were to be judged relatively rather than considered in terms of absolute success or failure. Furthermore results would be applicable to the ordinary routine of this particular clinic. The patients included in the control group were those in whom the initial diagnosis was made at a time when the doctor conducting the trial was not on duty. Again, the only cases excluded were those in patients who had already been treated for trichomonal infection in the previous 3 months.
Case material
The preliminary data on the trial and control patients are shown in Tables I and II. 
Results
The main results are shown in Table IV .
In the trial group of 102 patients, 73 returned for follow-up tests. After 4 weeks there had been nine recurrences of trichomoniasis, representing 12-3 per cent. of those followed. Only one further case of recurrence was revealed by later visits, bringing the final total to ten (13-7 per cent.) of those followed.
In the control group of 101 patients sixty returned for follow-up tests. After 4 weeks there had been four recurrences, representing 6-7 per cent. of those followed, but later visits revealed a further five recurrences, bringing the final total to nine (15 per cent.) of those followed.
Thus, although the early results showed about twice as many recurrences in the trial group as in the control group, the final figures for recurrences showed essentially the same proportion in both groups. And even if one chooses to ignore the later recurrences in the control group, it will be seen that most of the extra failures with the 2g. dose occurred within the first week, and therefore caused very little inconvenience. The possibility that these early failures might, paradoxically, have been of benefit to the patients is discussed below. The trial was not designed to investigate any relationship with gonorrhoea and it is possible to envisage several factors which may have artifically influenced these findings. Nevertheless, it suggests that a failure to respond to a 2 g. dose of metronidazole might indicate the need for extra alertness to possible underlying gonococcal infection.
RELATIONSHIP OF RECURRENCES TO GONORRHOEA

RELATIONSHIP OF RECURRENCES TO CONSORT TREATMENT
No attempt was made to assess the adequacy of treatment of consorts, and it was hoped that any reinfections would be evenly distributed between the two groups. However, the preponderance of late recurrences in the control group might suggest that an even distribution had not occurred.
A further complication arose because four of the consorts of patients in the trial group were inadvertently treated with a 2 g. dose instead of the intended 200 mg. three times a day, and three of the four patients concerned were amongst the ten with recurrences. The main purpose of referring to them here is to point out that whereas a single 2 g. dose appears to offer satisfactory therapy in women, it does not follow that it will be satisfactory for their consorts.
SIDE-EFFECTS
The incidence of side-effects was based on spontaneous complaints; there were no direct enquiries. Three patients had considerable difficulty in swallowing the five tablets, but none failed to take them; each of them confessed to great difficulty in swallowing any tablets at any time, and it might be supposed that these are the ones who would benefit most from supervised therapy. Four patients complained of feeling slightly sick for from 6 to 48 hours after therapy, but none of these vomited. One patient complained of headache, nausea, vomiting, and general malaise, but, she explained, these symptom occurred whenever she took any type of tablet! SERUM LEVELS OF METRONIDAZOLE At least three cases of attempted suicide involving metronidazole have been reported. In one (Fluker, 1961) , a dose of 4-2 g., and in the other two (Lewis and Kenna, 1965) doses of 3-6 and 12 g. were taken with no serious consequences; unfortunately serum levels were not obtained in these patients. Kane, McFadzean, Squires, King, and Nicol (1961) reported blood levels in two patients taking metronidazole 200 mg. three times a day for 7 days. These are shown graphically in the Figure with the serum levels from six volunteers in the present series who took a single 2 g. dose. FIGURE Serum levels of metronidazole It will be seen that the standard dose produced serum levels of 4-5 ,tg./ml. during the period of therapy. After the 2 g. dose, high levels of 30-45 jig./ml. were found after 3 hrs., and levels of 47-5 ,ug./ml. after 24 hrs.; the two levels that were obtained after 48 hrs. were 0 5 and 0 7 ,ug./ml.
Testing in vitro has revealed that most strains are sensitive to levels of 0-25-0-125 jig./ml. (Jennison Stenton, and Watt, 1961) . Thus, the 2 g. dose gave trichomonicidal levels for at least 24 hrs. and possibly for 48 hrs., and produced up to 30 to 40 times the trichomonicidal level shortly after administration.
Discussion
The introduction of metronidazole in 1959 transformed the management of trichomoniasis. Success rates with earlier treatments ranging from 30 per cent. (Pearson, 1957) down to 0 per cent. (Willcox, 1957) were replaced by reports of 86 per cent. (Rodin, King, Nicol, and Barrow, 1960) , 95 per cent. (Willcox, 1960) , and even 100 per cent. success (Keighley, 1962) . The high therapeutic index (Cosar and Julou, 1959) and the rapid excretion rate (Kane and others, 1961) make metronidazole a very safe drug, and the trial reported here shows that it is certainly effective in large single doses. No adverse effects have been reported with its use in pregnant women (Perl, 1965; Peterson, Hansen, Stauch, and Ryder, 1966; ScottGray, 1964) In a control group of 101 cases treatmnent was by 200 mg. metronidazole three times daily for 7 days. Recurrence rates in those followed up were ten of 73 (14 per cent.) and nine of sixty (15 per cent.) respectively. Most recurrences in the trial group were in the first month (four in the first week), whereas in the control group half the recurrences were in the 4th to 12th week period. There was an apparent relationship between failure with the 2 g. dose and the presence of gonorrhoea, undetected at the time.
Side-effects were limited to nausea in four cases and vomiting in one. It was concluded that the single oral dose of 2 g. was an acceptable treatment for vaginal trichomoniasis. 
